Table 5.
Economic costs and benefits among cancer cases diagnosed between 2020 and 2030 (11 modelled cancers) (all results discounted 3% annually)
| Incremental cancer
treatment costs (2020-2030), $ billion (95% uncertainty interval) |
Lifetime return on
investment: Full Income [2.3x GDP], (95% uncertainty interval) |
||||
|---|---|---|---|---|---|
| Difference | Percent increase |
Productivity gains, $ billion |
Net benefit, $ billion | Return per $ invested |
|
| Global | |||||
| Imaging only | 6.84 (1.77-15.86) | 0.2% (0.1-0.3) | 1,226.21 (540.05-2,161.8) | 1,219.37 (535.47-2,157.29) | 179.19 (84.71-625.09) |
| Treatment only | 50.72 (14.92-111.88) | 1.5% (0.8-2.4) | 1,183.24 (504.9-2,206.54) | 1,132.51 (489.13-2,114.69) | 23.33 (12.40-60.40) |
| Treatment + quality | 225.50 (83.87-408.34) | 6.7% (5.7-7.8) | 1,386.07 (726.42-2,342.19) | 1,160.56 (484.04-2,053.7) | 6.15 (2.66-16.71) |
| Comprehensive | 232.88 (85.92-421.97) | 6.9% (6.0-8.0) | 2,894.41 (1,794.55-4025.16) | 2,661.54 (1,631.20-3,775.64) | 12.43 (6.47-33.23) |
| Africa | |||||
| Imaging only | 0.46 (0.23-0.79) | 1.9% (1.2-3.0) | 27.38 (9.61-65.80) | 26.93 (9.29-65.34) | 59.97 (22.11-128.14) |
| Treatment only | 6.85 (3.82-11.22) | 29.4% (17.6-42.2) | 120.97 (52.46-210.96) | 114.12 (44.51-203.06) | 17.67 (8.09-33.93) |
| Treatment + quality | 11.14 (6.64-16.98) | 47.8% (34.1-63.1) | 164.86 (88.57-237.47) | 153.72 (79.95-225.41) | 14.80 (8.05-25.71) |
| Comprehensive | 11.67 (7.01-17.70) | 50.1% (36.2-66.4) | 249.66 (187.61-303.31) | 237.99 (177.71-291.8) | 21.39 (14.15-34.34) |
| Asia | |||||
| Imaging only | 3.42 (0.66-9.37) | 0.4% (0.1-0.6) | 713.38 (86.71-1,616.35) | 709.96 (86.03-1,610.45) | 208.70 (77.77-850.18) |
| Treatment only | 24.58 (4.35-69.42) | 2.7% (0.5-6.2) | 679.76 (107.85-1,681.10) | 655.17 (103.01-1,621.55) | 27.65 (12.89-68.97) |
| Treatment + quality | 37.98 (13.16-86.15) | 4.4% (1.9-8.5) | 772.73 (182.13-1,686.61) | 734.75 (164.77-1,613.12) | 20.35 (8.10-49.52) |
| Comprehensive | 41.59 (14.76-91.25) | 4.7% (2.3-8.9) | 1,653.82 (828.58-2,458.01) | 1,612.22 (802.55-2,410.54) | 39.76 (17.99-101.74) |
| Europe | |||||
| Imaging only | 1.95 (0.23-5.52) | 0.2% (0.0-0.4) | 281.15 (77.79-612.65) | 279.20 (76.86-605.35) | 144.32 (71.07-686.83) |
| Treatment only | 14.73 (1.88-38.95) | 1.2% (0.2-2.6) | 257.18 (82.05-517.31) | 242.45 (72.14-493.25) | 17.46 (8.28-66.89) |
| Treatment + quality | 171.39 (59.5-314.06) | 14.5% (13.3-16.0) | 301.80 (114.77-602.30) | 130.41 (−119.56-444.47) | 1.76 (0.49-6.02) |
| Comprehensive | 173.59 (59.79-315.94) | 14.7% (13.6-16.1) | 618.57 (367.27-884.37) | 444.98 (160.23-737.88) | 3.56 (1.64-10.47) |
| Latin America and the Caribbean | |||||
| Imaging only | 0.52 (0.03-1.31) | 0.6% (0.0-1.1) | 138.85 (8.89-259.83) | 138.33 (8.85-259.06) | 266.38 (109.69-1,351.47) |
| Treatment only | 2.21 (0.20-7.03) | 2.9% (0.3-7.4) | 79.99 (8.78-241.17) | 77.79 (8.54-237.43) | 36.28 (14.10-152.10) |
| Treatment + quality | 2.56 (0.45-7.42) | 3.4% (0.7-8.0) | 87.66 (9.42-264.11) | 85.10 (8.85-260.56) | 34.27 (12.16-124.16) |
| Comprehensive | 3.08 (0.61-8.04) | 4.1% (1.3-8.7) | 245.96 (123.82-403.20) | 242.88 (122.20-397.69) | 79.77 (30.36-384.86) |
| Northern America | |||||
| Imaging only | 0.37 (0.00-3.26) | 0.0% (0.0-0.2) | 47.48 (0.00-348.01) | 47.12 (0.00-345.16) | 128.94 (64.85-361.54) |
| Treatment only | 1.22 (0.00-11.54) | 0.1% (0.0-0.8) | 24.24 (0.00-202.14) | 23.02 (0.00-181.52) | 19.83 (7.95-72.25) |
| Treatment + quality | 1.22 (0.00-11.54) | 0.1% (0.0-0.8) | 32.60 (0.00-202.14) | 31.37 (0.00-190.39) | 26.66 (8.18-1,398.67) |
| Comprehensive | 1.59 (0.00-11.58) | 0.1% (0.0-0.8) | 80.12 (0.00-373.7) | 78.53 (0.00-371.43) | 50.36 (8.42-984.28) |
| Oceania | |||||
| Imaging only | 0.13 (0.00-0.59) | 0.1% (0.0-0.6) | 17.96 (0.13-77.95) | 17.83 (0.13-77.42) | 137.36 (24.94-338.03) |
| Treatment only | 1.14 (0.02-4.59) | 1.2% (0.0-4.4) | 21.09 (0.12-86.53) | 19.96 (0.11-83.31) | 18.56 (5.28-51.96) |
| Treatment + quality | 1.21 (0.09-4.68) | 1.3% (0.1-4.5) | 26.42 (0.67-93.98) | 25.21 (0.57-91.45) | 21.77 (5.70-191.78) |
| Comprehensive | 1.35 (0.13-4.83) | 1.4% (0.2-4.5) | 46.29 (9.13-112.39) | 44.95 (8.92-109.14) | 34.41 (11.48-244.48) |
Estimates are from the global cancer survival microsimulation model.55